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Abstract
This study tested the hypothesis that socioeconomically vul-
nerable Canadians with diverse acute conditions or chronic dis-
eases have health care access and survival advantages over their
counterparts in the USA. A rapid systematic review retrieved 25
studies (34 independent cohorts) published between 2003 and
2018. They were synthesized with a streamlined meta-analysis.
Very low-income Canadian patients were consistently and highly
advantaged in terms of health care access and survival compared
with their counterparts in the USA who lived in poverty and/or
were uninsured or underinsured. In aggregate and controlling for
specific conditions or diseases and typically 4 to 9 comorbid fac-
tors or biomarkers, Canadians’ chances of receiving better health
care were estimated to be 36% greater than their American coun-
terparts (RR=1.36, 95% CI 1.35-1.37). This estimate was signifi-
cantly larger than that based on general patient or non-vulnerable
population comparisons (RR=1.09, 95% CI 1.08-1.10). Contrary
to prevalent political rhetoric, three studies observed that
Americans experience more than twice the risk of long waits for
breast or colon cancer care or of dying while they wait for an
organ transplant (RR=2.36, 95% CI 2.09-2.66). These findings
were replicated across externally valid national studies and more
internally valid, metropolitan or provincial/state comparisons.
Socioeconomically vulnerable Canadians are consistently and
highly advantaged on health care access and outcomes compared
to their American counterparts. Less vulnerable comparisons
found more modest Canadian advantages. The Affordable Care
Act ought to be fully supported including the expansion of
Medicaid across all states. Canada’s single payer system ought to
be maintained and strengthened, but not through privatization.
Introduction
Canadians and Americans rate health care a top concern. They
seem naturally to wonder if health care policies are greener on the
other side of their unfenced 5,000-kilometer border. Some
Americans − particularly concerned with health care inaccessibil-
ity among the uninsured − have called for a more Canada-like sin-
gle payer system. In contrast, some Canadians − concerned with
health care shortages − have called for a more American-like sys-
tem with more private options. Aiming to contribute critical evi-
dence to these debates, our research group has focused on the
health care of people living in poverty. We assume that this mag-
nifies human and policy significance.
Canada-USA comparative studies of health care among over-
all populations can be misleading. For example, the first study to
compare Canada and the USA on cancer survival − a 1994 USA
General Accounting Office study − observed no practically signif-
icant between-country differences.1 Not accounting for socioeco-
nomic factors, its null findings were not surprising as gross com-
parisons of diverse national haystacks will necessarily lose impor-
tant needles of knowledge. Consider the great diversity of people
and places in Canada and the USA: women and men, the unin-
sured to the well-insured, recently emigrated ethnic minority peo-
ple of color to European white people who landed generations
ago, residents of megalopolises to remote places, high poverty to
affluent neighborhoods and so on. Any study of diverse national
populations that merely reports an average effect will miss knowl-
edge about the unique experiences of important subpopulations.
Alternatively, our research group’s study of cancer survival among
the poor in Toronto, Ontario and Detroit, Michigan during the
same era found substantially higher survival rates among
Canadians.2 Though geographically limited, it suggested that this
field’s scholars and policy makers ought to include socioeconomic
factors in their designs and decisions. 
Joint Canada/USA surveys have consistently demonstrated
greater income-related health, health care and mortality disparities
in the USA.3-5 Similar surveys of the poor in each country found
them to be healthier and with greater health care access in
Canada.6,7 With unanimity, these studies advanced universal, sin-
gle payer health insurance coverage as a key explanation for
Canadian advantages. Notwithstanding cross-sectional limita-
tions, they essentially developed a health insurance hypothesis
that others have tested with more rigorous, longitudinal methods
over a generation. The findings of 64 such Canada-USA longitu-
dinal comparative outcome studies published between 1965 and
2000 were synthesized between 1999 and 2009 in two systematic
reviews of diverse health outcomes and a meta-analysis of breast
cancer survival.8-10
Significance for public health
This study estimated that socioeconomically vulnerable Canadians’ chances
of receiving better health care were 36% greater than their American coun-
terparts and this estimate was larger than that based on general patient
comparisons (9%). One may wonder about the public health significance of
such relative risks/protections. Attributions of risk/protection among popula-
tions are a function of three factors of which relative risk is only one. The
size of the population and the prevalence of exposure to risks are also impor-
tant. In this instance, the entire USA population is at relatively greater risk
of receiving lower quality care, its more prevalent low-income and inade-
quately insured populations more so. Applying our findings to population
parameters and attributable risk formulations we estimated that without
reform, over the next generation more than 50 million Americans will be
treated less optimally and die earlier than had they enjoyed a single-payer
health care system like Canada’s.
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Previous research syntheses
This field’s first systematic review of 18 studies of health care
among patients with diverse acute conditions or chronic diseases
found few differences between both countries on relevant outcomes
such as mortality.8 As none of the primary studies accounted for
socioeconomic factors, neither could the review. More fundamen-
tally though, many studies of that era could not even account for
between-country differences on disease severity. For example, at
that time no Canadian cancer registry yet included disease stage at
diagnosis. Hence, Canada-USA cancer care comparisons could not
account for such basic case-mix differences. However, this early
review made an extraordinarily valuable heuristic contribution. It
clarified the fact that this field’s extant research was not yet rigor-
ous enough to inspire confident judgements about the relative
effectiveness of Canadian versus American health care. It also
highlighted future research that would be needed to make confi-
dent decisions.
Nearly a decade later, a greater number of similarly limited
studies of diverse Canadian and American patients were systemat-
ically reviewed.9 Fourteen studies observed Canadian advantages,
5 observed USA advantages and 19 were null. Overall, the risk of
mortality was estimated to be 5% lower among Canadians. Such
inconsistent and modest between-country differences could as
plausibly be due to unaddressed confounding or effect modifica-
tions as to true health care differences. This review team also found
that the one disease for which results consistently favored
Canadians was end-stage renal disease. The high costs and
resource utilization associated with this chronic condition are
much better managed in Canada’s predominantly not-for-profit
system. This is another element of patient case-mix − chronic dis-
eases versus acute conditions − to consider in future syntheses. 
The third research synthesis, a meta-analysis of 8 breast cancer
survival studies, one of which was stage-adjusted, did incorporate
socioeconomic factors.10 Among low-income women, it estimated
a Canadian survival advantage of 14% (sample-adjusted rate ratio
[RR]=1.14, 95% CI 1.13-1.15) that was even larger among
younger women who were not yet Medicare eligible in the USA
(RR=1.21, 95% CI 1.17-1.25). No between-country survival dif-
ference was observed among its aggregated middle- and high-
income groups. However, its ecologically-defined low-income
neighborhoods were typically places where only 10% to 15% of
the residents were poor. None studied sociologically well-known
high poverty neighborhoods where 30% to 40% or more of the
people were poor.11,12 This research synthesis recommended future
primary studies in such vulnerable places and accounting for other
aspects of place such as residence in large urban, small urban or
rural places as they represent very different health care endow-
ments in both countries. 
This review aims to systematically update this field’s knowl-
edge, incorporating as many of the previous reviewers’ suggestions
as its primary studies allow. We posed three questions: 
(1) Compared to Americans, are Canadians advantaged on health
care access and outcomes? 
(2) Are Canadian advantages larger among socioeconomically
vulnerable people? 
(3) Are Canadian advantages larger among people with chronic
diseases than acute conditions?
Materials and Methods
Traditional interdisciplinary methodological frameworks were
used to guide the process and presentation of this systematic
review.13-15 Methodological guidance of teams of researchers and
knowledge users on both sides of the Canada-USA border allowed
us to gain efficiencies and compress the review time period.16,17
The rapid systematic review included a classical, but also stream-
lined meta-analysis to gain specific knowledge about the relative
effectiveness of health care in Canada and the USA, particularly
among socioeconomically vulnerable subpopulations with specific
acute conditions or chronic diseases.18-20
Selection of studies
This field’s last systematic review searched until December 31,
2002. The following research or gray literature databases were
searched between January 1, 2003 and January 1, 2019: PubMed,
Medline, CINAHL Complete, ProQuest Nursing and Allied Health
Database, EBM Reviews, HealthSTAR, Social Work Abstracts,
Social Services Abstracts, ProQuest Sociology Collection,
ProQuest Dissertations and Theses, Conference Proceedings
Citation Indexes − Science and Social Sciences & Humanities, and
Google Scholar. Detailed keyword search schemes are summa-
rized as follows: (Canada or any of 13 provinces or territories) and
(United States or USA or any of 50 states) and (health care access
or treatment or outcome or survival or for example, asthma or heart
attack or MI or coronary heart disease or CHD or cancer or any of
the most common acute conditions or chronic diseases). Any
observational study of any physical health condition or disease
with an indicated treatment or well-defined outcome was included. 
In an effort to find studies specifically about socioeconomical-
ly vulnerable subpopulations, the searches were then systematical-
ly replicated with addition of the following keyword set: (poverty
or income or socioeconomic factors or health insurance or unin-
sured). Study exclusion criteria were: (1) published in 2003, but
included in the previous review, (2) opinion surveys of patients or
practitioners, (3) randomized controlled trials as they may not
reflect typical patients or typical care, (4) national mortality studies
that confound disease incidence and survival or (5) studies of men-
tal health. For scholarly and policy reasons we think that mental
health care warrants a separate research review; one we are
presently scoping.21,22 Searches were augmented with bibliograph-
ic reviews of retrieved studies. Searches of their authors were also
performed. Three reviewers, one an experienced academic librari-
an, independently searched for eligible studies. When two review-
ers suggested eligibility based on study titles and abstracts, it was
included. If in the review of full study manuscripts any research
team member suspected ineligibility, a consensus decision was
reached after discussion. Twenty-five studies were so selected.23-47
Meta-analysis
The unit of analysis for this meta-analysis was the unique
hypothesis test. Between-country comparisons were observed for
treatment access or outcomes among overall samples or socioeco-
nomically vulnerable subsamples. These were treated as indepen-
dent hypotheses. Each study could contribute only once to each
hypothesis test. If a primary study provided three outcomes all
related to the same hypothesis, for example, 1, 3 and 5-year sur-
vival among colon cancer patients living in poverty, the three esti-
mated survival rate ratios would be pooled so that that study would
contribute one data point for that meta-analytic hypothesis test. A
total of 34 such independent study findings were included in this
meta-analysis.
Treatment or survival rate ratios, odds ratios, hazard ratios or
similar measures of effect estimated primary study relative risks
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(RR). Natural logarithms of study RRs were weighted by their
inverse variances, computed from standard errors (1/SE2) so that
larger, more precise studies carried more weight. Standard errors
were estimated from study statistics, generally from reported 95%
CIs. Such precision-weighted effects were then pooled within
domains of interest using weighted regression models. Pooled RRs
within 95% CIs were calculated from regression statistics, as were
tests of heterogeneity (χ2) and meta-analytic between-groups com-
parisons (z). All statistical significance decisions were made at the
α criterion of 0.05. For ease of interpretation, all RRs greater than
1.00 indicated a Canadian advantage, while those less than 1.00
indicated an American advantage. Study hypotheses were so test-
ed: (1) Compared to Americans, Canadians are advantaged on
health care access and outcomes (primarily survival). (2) Canadian
advantages are larger among socioeconomically vulnerable people.
(3) Canadian advantages are larger among people with chronic dis-
eases than acute conditions. Meta-analytic hypotheses were inde-
pendently tested and cross-validated by two analysts.
As expected, given the sociodemographic, geographic, clinical
and methodological variability, the 34 independent primary study
outcomes demonstrated substantial heterogeneity (χ2 [33] =
26,565.00, P<0.05) around a hypothetically supportive precision-
adjusted pooled Canadian advantage of 13% (RR=1.13, 95% CI
1.12-1.14). Our central hypothesized moderators of socioeconomic
factors and disease chronicity aim to explain such variability. In
fact, we expected and found substantial effect homogeneity within
specific groups of interest after accounting for disease and socioe-
conomic status. For example, focusing on guideline-based treat-
ment access among women living in poverty with breast cancer,
the 3 relevant study outcomes demonstrated essentially no hetero-
geneity (χ2 [2] = 0.01, P=0.99) around a precision-adjusted pooled
Canadian advantage of 75% (RR=1.75, 95% CI 1.64-1.87).45-47
Therefore, the potential moderating effects of study characteristics
were explored with fixed-effects meta-regressions. In addition to
hypothetically noted characteristics, this streamlined meta-analysis
explored the following patient, contextual and research design
characteristics: age, gender, ethnicity, health insurance status,
large/small urban/rural places, historical/prospective cohort,
cohort timeframe, study sample sizes, geographic sampling frames
(national/provincial-state/metropolitan), clinic or population-
based, primary/administrative data, number of analytic comorbid
factors or biomarkers, and follow-up rates. Study characteristics
were abstracted independently from full primary study
manuscripts by two reviewers. After discussion and resolution of
discrepancies their agreement was 100%.
Results
Sample description
Descriptive details of the 19 overall population and 15 socioe-
conomic subpopulation study outcomes are respectively presented
in Tables 1-3. Socioeconomically vulnerable subpopulations
included those who lived in poverty in Canada and the USA and/or
were uninsured or inadequately insured in the USA. All unique
study hypotheses, based on unique subsamples, treatments or out-
comes, are displayed along with their within-study pooled RRs.
Descriptive summaries of participant and study characteristics are
displayed in Table 4. Half of the study outcomes were of cancer,
most prevalently breast or colon cancer. This is perhaps not sur-
prising given the comprehensiveness and validity of contemporary
cancer registration in both countries. Representing a distinct
advancement over such previously reviewed studies, nearly all of
the cancer analyses were minimally case-mix adjusted for age and
stage of disease at diagnosis. Otherwise, the diverse acute condi-
tions or chronic diseases displayed in the top of Table 4 seem a fair
representation of interesting and important health care indicators
studied over the life course from infancy to older adulthood.
Twenty-four outcomes combined effects for women and men,
treating gender as a covariate. Ten outcomes were of women only,
while there were no exclusively male outcomes. Seven studies
accounted for race/ethnicity, but again, only as a covariate. No spe-
cific racialized/ethnic group outcomes were reported.
A quarter of the study outcomes were nationally representa-
tive. Another 60% or so were representative of single or multiple
provinces and states. The remainder were single metropolitan area
investigations. Research designs were predominantly historical
cohorts (82%) initiated in the 1990s (65%). Aggregated study sam-
ples ranged from 62 to 120,117, the median being 2,306 partici-
pants. About two-thirds of the study outcomes were based on quite
powerful samples of 1,000 to 25,000 or more, emphasizing exter-
nal validity. Another third of the outcomes were based on smaller
and better controlled investigations, emphasizing internal validity.
Consistent with the prevalent use of well-supported and validated
administrative data, most of the analyses lost less than 1% of their
original participants to follow-up. Three outcomes of one study
reported differential losses (2.5% in Canada vs 5.5% in the
USA),34 but such only made these comparisons conservative. As
mentioned, all the primary analyses accounted for at least two
covariates. Typically, they accounted for 4 to 9 such comorbid fac-
tors or biomarkers. Finally, 10 measures of treatment access and 24
treatment outcome measures, typically survival, were represented.
In fact, we think that most, if not all, of the mortality outcomes
were actually measures of survival. As the studies typically fol-
lowed a well-defined diagnostic group in a similar manner, sur-
vival is probably not confounded by condition or disease inci-
dence. The primary studies included in this review seem more rig-
orous than previously reviewed studies as a larger portion of the
studies used well-controlled cohort designs. 
Meta-analytic findings
In support of the first hypothesis, 25 study observations indi-
cated Canadian health care advantages, 3 observed USA advan-
tages and 6 were null. The chances of receiving health care in a
timely manner and surviving were estimated to be 13% greater
among Canadians (RR=1.13, 95% CI 1.12-1.14) than Americans.
Meta-analytic findings related to hypotheses two and three are dis-
played in Table 5. In support of hypothesis two, all 15 observations
of socioeconomically vulnerable people indicated Canadian
advantages, though 1 only approached statistical significance.
Their chances of receiving better health care were estimated to be
36% greater than their American counterparts (RR=1.36, 95% CI
1.35-1.37). This Canadian advantage was significantly and sub-
stantially larger than that estimated with 19 overall samples of
patients; z=48.47, P<0.05: 10 observed Canadian advantages, 3
USA advantages and 6 were null (RR=1.09, 95% CI 1.08-1.10).
Furthermore, statistically and practically larger Canadian advan-
tages were replicated among socioeconomically vulnerable
patients with acute conditions (RR=1.14 vs RR=1.03) and chronic
diseases (RR=1.37 vs RR=1.12). Because one of us (KMG) pro-
duced 12 of the 15 socioeconomically vulnerable population com-
parisons we performed a sensitivity analysis. The pooled effect of
KMG’s research group (RR=1.35, 95% CI 1.34-1.36) did not differ
significantly from that of three other research groups (RR=1.38,
95% CI 1.35-1.41), z=0.19, P=0.85. Hypothesis three was also
consistently supported. Within overall Canada-USA comparisons
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Table 1. Description and outcomes of studies included in the rapid review and meta-analysis: Overall Canada and USA comparisons
(acute conditions).
Reference                             Clinical population, ages                                         Research design                                                Outcome
                                                             Places                                                               Selection                                    Canada vs USA adjusted rates
                                                        Cohort years                                                   Analytic samples                                              Risk ratiob
                                                Other characteristics                                      Covariate adjustmentsa                                         95% confidence interval
Acute decompensated heart failure
Lai et al. 2016                                                  ADHF in ED, 18 or older                                                                       Historical cohort                                                                     30-day mortality
                                                                 Ottawa, ON & Rochester, MN 2010                                                    Population, health records                                                               5.1% vs 9.7%
                                                                                         1 & 1 ED                                                                                            156 & 165                                                                                 OR = 1.99
                                                                                                                                                                    Age, gender, 5 comorbidities & 3 biomarkers                                          95% CI: 0.83, 4.78
Acute myocardial infarction
Ko et al. 2007                                         Hospitalized with AMI, 65 or older                                                              Historical cohort                                                    30-day risk-standardized mortality
                                                                                   Ontario & USA                                                                     Random, administrative data                                                            16.6% vs 17.3%
                                                                                      1998 to 2001                                                                                     5,634 & 38,886                                                                            SMR = 1.05
                                                                             All Medicare covered                                                Age, gender, 7 comorbidities & 7 biomarkers                                          95% CI: 0.99, 1.11c
Ko et al. 2007                                                                        //                                                                                                           //                                                                   1-year risk-standardized mortality
                                                                                                                                                                                                                                                                                                   27.7% vs 31.9%
                                                                                                                                                                                                                                                                                                      SMR = 1.15
                                                                                                                                                                                                                                                                                                 95% CI: 1.06, 1.25
Ko et al. 2007                                                                        //                                                                                                           //                                                                   3-year risk-standardized mortality
                                                                                                                                                                                                                                                                                                   40.3% vs 45.9%
                                                                                                                                                                                                                                                                                                      SMR = 1.14
                                                                                                                                                                                                                                                                                                 95% CI: 1.05, 1.23
                                                                                                                                                                                                                                                                             [SMRpooled = 1.08, 95% CI: 1.06, 1.10]
Appendicitis
Cheong & Emil 2014                          Pediatric appendectomy, less than 18                                                           Historical cohort                                                              Perforated appendicitis
                                                                      Canada (not Quebec) & USA                                                     Population, administrative data                                                         27.3% vs 26.7%
                                                                                      2004 to 2010                                                                                    41,492 & 78,625                                                                            RR = 0.98
                                                                                      All insurers                                                                                     Age & gender                                                                       95% CI: 0.96, 1.00
Asthma
Rowe et al. 2007                                     Acute asthma in ED, ages 2 to 54                                                             Prospective cohort                                                                2-week ED relapse
                                                                                   Canada & USA                                                                         Population, primary data                                                                          nd
                                                                                      1996 to 1998                                                                                       136 & 2,198                                                                                OR = 0.63
                                                                8 & 69 EDs, 4 provinces & 22 states                                     Age, gender, race, income & 4 biomarkers                                             95% CI: 0.30, 1.43
COPD
Rowe et al. 2008                                       Exacerbated COPD in ED, M 70                                                              Prospective cohort                                                              2-week ED relapse
                                                                                   Canada & USA                                                                         Population, primary data                                                                          nd
                                                                                      1999 to 2001                                                                                         58 & 291                                                                         RR = 0.30
                                                                5 & 24 EDs, 3 provinces & 15 states                                            Age, gender, race, income, BMI                                             95% CI: 0.01, 6.09
                                                                                                                                                                             4 comorbidities & 6 biomarkers                                                            
Cataract surgery
Norregaard et al. 2003            Unilateral cataract surgery, 50 or older                                             Prospective cohort                                               4-month visual functioning
                                                                        Manitoba & USA                                                           Consecutive, primary data                                                               nd
                                                                            1993 to 1994                                                                              111 & 570                                                                       OR = 1.00
                                                         12 & 75 ophthalmology practices                                    Age, gender, general health status                                          95% CI: 0.96, 1.26
                                                                                                                                                             1 comorbidity & 3 biomarkers                                                              
Gastroschisis
Youssef et al. 2003                       Simple gastroschisis, newborns                                                   Prospective cohort                                                      Inpatient mortality
                                                                          Canada & USA                                                  Population, registry & administrative                                            1.4% vs 3.4%
                                                                            2003 to 2013                                                                            584 & 4,502                                                                      RR = 2.43
                                                                         16 & 345 NICUs                                                                        Age, gender                                                               95% CI: 1.27, 4.65
                                                                                                                                                           3 comorbidities & 3 biomarkers
Youssef et al. 2003                                Complex gastroschisis                                                                    111 & 714                                                                    10.8% vs 9.3%
                                                                                                                                                                                                                                                                         RR = 0.86
                                                                                                                                                                                                                                                                   95% CI: 0.51, 1.46
                                                                                                                                                                                                                                                   [RRpooled = 1.34, 95% CI: 1.12, 1.60]
ADHF, acute decompensated heart failure; AMI, acute myocardial infarction; BMI, body mass index; CT, census tract; CABG, coronary artery bypass graft; COPD, congestive obstructive pulmonary disease; ED, emergency
department; ESRD, end-stage renal disease; HR, hazard ratio; IMR, infant mortality ratio; M, mean; Mdn, median; MMR, maternal mortality ratio; nd, no data; NICU, neonatal intensive care unit; OR, odds ratio; PM, person
months; PY, person years; RR, rate ratio; SEER, Surveillance, Epidemiology and End Results program; SES, socioeconomic status; SMR, standardized mortality ratio. aPotential confounds that were accounted for by sam-
ple restriction, matching or mathematical/regression modeling.  bRisk ratios were adjusted in regressions or directly standardized. Risk ratios greater than 1.00 indicate a Canadian advantage while those less than 1.00
indicate a USA advantage. cP = 0.10. dUnadjusted rates. 
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Table 2. Description and outcomes of studies included in the rapid review and meta-analysis: Overall Canada and USA comparisons
(chronic disease).
Reference                     Clinical population, ages                                       Research design                                            Outcome
                                                     Places                                                            Selection                                Canada vs USA adjusted rates
                                                Cohort years                                                 Analytic samples                                           Risk ratiob
                                        Other characteristics                                    Covariate adjustmentsa                                    95% confidence interval
Cancer
Bremner et al.2015               Advanced lung cancer, 65 or older                                                      Historical cohort                                                 Received home health care
                                                            Ontario & USA (SEER)                                                       Population, registry-based                                                    57.5% vs 20.1%
                                                                      2001 to 2005                                                                             8,643 & 16,858                                                                    RR = 2.86
                                                             All Medicare covered                                                     Age, stage & health insurance                                               95% CI: 2.77, 2.95
Gorey et al. 2011                            Colon cancer, 25 or older                                                              Historical cohort                                                             5-year survival
                                                  Toronto, ON & San Francisco, CA                                                Random, registry-based                                                                 nd
                                                                      1996 to 2006                                                                               930 & 1,014                                                                      OR = 0.94
                                                                All income groups                                                                 Age, stage & gender                                                        95% CI: 0.68, 1.29
Gupta et al. 2009          Upper aerodigestive tract cancer, M 64 & 62                                            Historical cohort                                                     5-year relative survival
                                                            Ontario & USA (SEER)                                                       Population, registry-based                                                    57.1% vs 52.4%
                                                                      1999 to 2006                                                                              3,262 & 8,399                                                                     RR = 1.09
                                                          Most recent of 6 cohorts                                                 Age, gender & mortality causes                                             95% CI: 1.05, 1.13
Warren et al. 2011            Non-small cell lung cancer, 65 or older                                                 Historical cohort                                           Received palliative chemotherapy
                                                            Ontario & USA (SEER)                                                       Population, registry-based                                    20.6 vs 10.9 patients per 100 PM
                                                              Last 5 months of life                                                        Age, sex, income & urbanity                                       95% CI: 0.36, 0.78 RR = 0.53 
Cystic fibrosis
Stephenson et al. 2017                  Cystic fibrosis, all ages                                                                Historical cohort                                                                   Survival
                                                                    Canada & USA                                                               Population, registry-based                                     50.9 & 40.6 median survival age
                                                                      2009 to 2013                                                                             4,662 & 32,699                                                                    HR = 1.52
                                                                      All insurers                                       Age, gender, race, BMI, 3 comorbidities & 5 biomarkers                       95% CI: 1.23, 1.85
Stephenson et al. 2017                                       //                                                                                                   //                                                                  Received lung transplant
                                                                                                                                                                                                                                                                    10.3% & 6.5%
                                                                                                                                                                                                                                                                       RR = 1.58
                                                                                                                                                                                                                                                       95% CI: 1.44, 1.74 RR = 0.53 
End-stage renal disease
Hladunewich et al. 2014               Hemodialysis, M 27 & 34                                                Prospective & historical cohorts                                               Live birth rate
                                                               Toronto, ON & USA                                                   Population, registry-based 19 & 43                                            84.4% & 61.4%d
                                                        2000 to 2013 & 1990 to 2011                                                            Age, ESRD cause                                                                 HR = 1.37
                                                       Pregnant women with ESRD                                                       National MMR & IMR                                                       95% CI: 1.04, 1.80
Kim et al. 2006                 Kidney transplant recipients, 18 or older                                                Historical cohort                                                   Post-transplant mortality
                                                        Canada & USA 1991 to 1998                                      Population, registry-based 5,773 & 70,708                       29.8 & 40.9 deaths per 1,000 PYd
                                                            End-stage renal diseas                                                   Age, gender, race, ESRD cause,                                                    HR = 1.35
                                                                                                                                                     Time on dialysis, year of transplant                                          95% CI: 1.24, 1.47
Quinn et al. 2010                       Peritoneal dialysis, M 54 & 53                                                        Prospective cohort                                              Peritoneal dialysis mortality
                                                                    Canada & USA                                                      Consecutive, primary data 578 & 102                          98.5 & 157.9 deaths per 1,000 PYd
                                                                      1990 to 1993                                                               Age, gender, 2 comorbidities                                                      HR = 1.93
                                                     Kidney failure, 10 & 4 centers                                       2 biomarkers & background mortality                                        95% CI: 1.13, 3.28
Heart disease
Eisenberg et al. 2005                   CABG surgery, 21 or older                                                             Historical cohort                                                       In-hospital mortality
                                                                    Canada & USA                                                         Consecutive, administrative data                                                         nd
                                                       1997 to 2000 4 & 5 hospitals                                                               7,319 & 4,698                                                                     OR = 0.92
                                                                                                                                          Age, gender, previous CABG, elective or non- &                              95% CI: 0.62, 1.35
                                                                                                                                                                 7 comorbid conditions                                                                     
Ko et al. 2005                      Heart failure, hospitalized, 65 or older                                                  Historical cohort                                                            30-day mortality
                                                                   Ontario & USA                                                          Population, administrative data                                                 10.7% & 8.9%
                                                                      1998 to 2001                                                                             8,180 & 28,521                                                                  SMR = 0.83
                                                             All Medicare covered                                        Age, gender, 5 comorbidities & 5 biomarkers                                 95% CI: 0.77, 0.89
Ko et al. 2005                                                        //                                                                                                   //                                                             1-year mortality 32.3% & 32.2%
                                                                                                                                                                                                                                                     SMR = 1.00 95% CI: 0.96, 1.04
                                                                                                                                                                                                                                               [SMRpooled = 0.96, 95% CI: 0.95, 0.98]
Liver disease
Stell et al. 2004                Liver transplant recipients, Mdn 52 & 50                                                Historical cohort                                              1-year post-transplant survival
                                                               Canada & USA 2000                                                          Population, registry-based                                                    91.3% & 88.0%
                                                         First cadaveric transplant                                                                   308 & 3,364                                                                       RR = 1.04
                                                                                                                                               Age, sex, 4 comorbidities & 4 biomarkers                                    95% CI: 0.99, 1.09c
Stell et al. 2004                                                    //                                                                                                   //                                                                        Wait-list mortality
                                                                                                                                                                                                                                            3.1 vs 7.6 deaths per million population
                                                                                                                                                                                                                                                                       RR = 2.43
                                                                                                                                                                                                                                                                95% CI: 1.43, 4.14 
                                                                                                                                                                                                                                                [RRpooled = 1.05, 95% CI: 1.03, 1.07]
ADHF, acute decompensated heart failure; AMI, acute myocardial infarction; BMI, body mass index; CT, census tract; CABG, coronary artery bypass graft; COPD, congestive obstructive pulmonary disease; ED, emergency
department; ESRD, end-stage renal disease; HR, hazard ratio; IMR, infant mortality ratio; M, mean; Mdn, median; MMR, maternal mortality ratio; nd, no data; NICU, neonatal intensive care unit; OR, odds ratio; PM,
person months; PY, person years; RR, rate ratio; SEER, Surveillance, Epidemiology and End Results program; SES, socioeconomic status; SMR, standardized mortality ratio. aPotential confounds that were accounted
for by sample restriction, matching or mathematical/regression modeling.  bRisk ratios were adjusted in regressions or directly standardized. Risk ratios greater than 1.00 indicate a Canadian advantage while those
less than 1.00 indicate a USA advantage. cP = 0.10. dUnadjusted rates.
                                                                [Journal of Public Health Research 2019; 8:1479]                                                 [page 5]
No
n-c
om
me
rci
al 
us
e
nly
[page 6]                                                  [Journal of Public Health Research 2019; 8:1479]                            
                                Reviews and Meta-Analysis
Table 3. Description and outcomes of studies included in the rapid review and meta-analysis: Comparisons of socioeconomically vul-
nerable people in Canada and the USA.
Reference                     Clinical population, ages                                       Research design                                            Outcome
                                                     Places                                                            Selection                                Canada vs USA adjusted rates
                                                Cohort years                                                 Analytic samples                                           Risk ratiob
                                        Other characteristics                                    Covariate adjustmentsa                                    95% confidence interval
Acute conditions: Appendicitis
Cheong & Emil 2014          Pediatric appendectomy, less than 18                                                   Historical cohort                                                    Perforated appendicitis
                                                      Canada (not Quebec) & USA                                             Population, administrative data                                                27.3% vs 31.2%
                                                                      2004 to 2010                                                                            41,492 & 12,344                                                                   RR = 1.14
                                                                 Uninsured in USA                                                                        Age & gender                                                              95% CI: 1.05, 1.23
Chronic diseases: Cancer
Bremner et al.  2015             Advanced lung cancer, 65 or older                                                      Historical cohort                                                            180-day survival
                                                            Ontario & USA (SEER)                                                       Population, registry-based                                                    66.0% vs 61.5%
                                                                      2001 to 2005                                                                              3,071 & 5,215                                                                     RR = 1.07
                                                   Lowest Mdn income three-fifths                                           Age, stage & health insurance                                               95% CI: 1.04, 1.10
Gorey et al. 2017                           Breast cancer, 25 or older                                                             Historical cohort                                                   Received optimum cared
                                                              Ontario & California                                                            Random, registry-based                                                      38.1% vs 23.1%
                                                                      1996 to 2014                                                                               315 & 2,100                                                                       RR = 1.65
                                                  Very high poverty neighborhoodsc                 Age, stage, grade, tumor size & hormone receptor status                      95% CI: 1.39, 1.96
Gorey et al. 2017                        Publicly or uninsured in USA                                                                 315 & 974                                                                    38.1% vs 18.0%
                                                                                                                                                                                                                                                                       RR = 2.12
                                                                                                                                                                                                                                                                95% CI: 1.76, 2.56
                                                                                                                                                                                                                                              [RRpooled = 1.87, 95% CI: 1.77, 1.98]
Gorey et al. 2015a                    HR+ breast cancer, 25 or older                                                        Historical cohort                                                 Received hormone therapy
                                                              Ontario & California                                                            Random, registry-based                                                      68.2% vs 41.2%
                                                                      1996 to 2011                                                                                 216 & 993                                                                        RR = 1.65
                                                  Very high poverty neighborhoodsc                                        Age & hormone receptor status                                             95% CI: 1.44, 1.89
Gorey et al. 2015a                             Node negative, low or                                                                         85 & 624                                                                     64.0% vs 44.5%
                                                  Intermediate grade breast cancer                                         Age, stage, grade & tumor size                                       Received optimum caree
                                                                                                                                                                                                                                                                       RR = 1.44
                                                                                                                                                                                                                                                                95% CI: 1.16, 1.79
Gorey et al. 2015a                                Uninsured in USA                                                                             85 & 56                                                                      64.0% vs 33.8%
                                                                                                                                                                                                                                                                       RR = 1.89
                                                                                                                                                                                                                                                                95% CI: 1.31, 2.72
                                                                                                                                                                                                                                              [RRpooled = 1.62, 95% CI: 1.54, 1.70]
Gorey et al. 2015b        Non-metastasized colon cancer, 25 or older                                             Historical cohort                                                            10-year survival
                                                              Ontario & California                                                            Random, registry-based                                                      38.2% vs 33.3%
                                                                      1996 to 2011                                                                               692 & 1,496                                                                       RR = 1.15
                                                  Very high poverty neighborhoodsc                                                   Age, gender & stage                                                        95% CI: 1.02, 1.30
Gorey et al. 2015b                                All poverty groups                                                                        2,060 & 2,509                                                                 38.7% vs 32.8%
                                                       Publicly or uninsured in USA                                                                                                                                                           RR = 1.18
                                                                                                                                                                                                                                                                95% CI: 1.09, 1.28
                                                                                                                                                                                                                                              [RRpooled = 1.17, 95% CI: 1.13, 1.21]
Gorey et al. 2013                    Colon cancer, women, 25 or older                                                      Historical cohort                                                             7-year survival
                                                              Ontario & California                                                            Random, registry-based                                                      44.6% vs 38.4%
                                                                      1996 to 2011                                                                                 289 & 975                                                                        RR = 1.16
                                                  Very high poverty neighborhoodsc                                                    Age, stage & grade                                                         95% CI: 1.00, 1.35
Gorey et al. 2013                       Un- or Medicaid-insured in CA                                                                289 & 173                                                                    44.6% vs 30.7%
                                                                                                                                                                                                                                                                       RR = 1.45
                                                                                                                                                                                                                                                                95% CI: 1.14, 1.85
                                                                                                                                                                                                                                              [RRpooled = 1.23, 95% CI: 1.17, 1.29]
Gorey et al. 2013                    Very high poverty neighborhoodsc                                                              78 & 241                                                   Received adjuvant chemotherapy
                                                                                                                                                                                                                                                         Stage III: 45.1% vs 43.6%
                                                                                                                                                                                                                                                                       RR = 1.03
                                                                                                                                                                                                                                                                95% CI: 0.83, 1.28
Gorey et al. 2013                       Un- or Medicaid-insured in CA                                                                  78 & 54                                                                      45.1% vs 30.2%
                                                                                                                                                                                                                                                                       RR = 1.49
                                                                                                                                                                                                                                                                95% CI: 1.00, 2.25
Gorey et al. 2013                    Very high poverty neighborhoodsc                                                              55 & 229                                           Waited 60 days or more for chemotherapy
                                                                                                                                                                                                                                                     Stage II or III: 20.0% vs 37.7%
                                                                                                                                                                                                                                                                       RR = 1.89
                                                                                                                                                                                                                                                                95% CI: 1.14, 3.13
Gorey et al. 2013                       Un- or Medicaid-insured in CA                                                                  55 & 57                                                                       20% vs 59.8%
                                                                                                                                                                                                                                                                       RR = 2.99
                                                                                                                                                                                                                                                                95% CI: 1.82, 5.00
                                                                                                                                                                                                                                              [RRpooled = 1.35, 95% CI: 1.25, 1.45]
Continued on next page.
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(RR=1.12 vs RR=1.03) and within socioeconomically vulnerable
populations (RR=1.37 vs RR=1.14), Canadian advantages were
larger among people with chronic diseases. Finally, after account-
ing for socioeconomic factors and disease chronicity, no other pri-
mary study characteristic was significantly associated with
Canada/USA RRs. 
Discussion
This study found that Canadians with any number of acute
health conditions or chronic diseases are significantly more advan-
taged on health care access and outcomes compared to their coun-
terparts in the USA. It estimated that the chances of Canadians
receiving indicated treatments and surviving were 13% greater
than Americans. That estimate was more unequivocal and larger
than previous review estimates that were based on less internally
valid research designs. The most typical primary studies included
in this review were historical cohorts that accounted for 4 to 9
covariates in analyzing the experiences of 1,000 to 25,000 patients,
more than 99% of whom were available for assessment at follow-
up. As with primary research however, such a meta-analytic main
or average effect can be misleading. Therefore, we advanced and
found much support for a meta-analytic country by socioeconomic
status interaction. This clearly demonstrated that Canadian advan-
tages were significantly larger among those living in poverty or
those who were otherwise socioeconomically vulnerable such as
the uninsured or inadequately insured. 
Among patients who lived in high poverty neighborhoods, it
was estimated that the chances of Canadians receiving indicated
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Table 3. Continued from previous page. 
Reference                     Clinical population, ages                                       Research design                                            Outcome
                                                     Places                                                            Selection                                Canada vs USA adjusted rates
                                                Cohort years                                                 Analytic samples                                           Risk ratiob
                                        Other characteristics                                    Covariate adjustmentsa                                    95% confidence interval
Gorey et al. 2011                            Colon cancer, 25 or older                                                              Historical cohort                                                             5-year survival
                                                  Toronto, ON & San Francisco, CA                                                Random, registry-based                                                                 nd
                                                                      1996 to 2006                                                                                 231 & 247                                                                        OR = 2.51
                                                          Lowest income (%) third                                                           Age, stage & gender                                                        95% CI: 1.52, 4.15
                                                                                 
Gorey et al. 2011                                        1996 to 2002                                                                                 291 & 273                                                  Received adjuvant chemotherapy
                                                    Lowest income (%) two-thirds                                                                                                                                       Stage II or III: 57.3% vs 34.3%
                                                                                                                                                                                                                                                                       RR = 1.67
                                                                                                                                                                                                                                                                95% CI: 1.06, 2.64
Gorey et al. 2010a           Node negative breast cancer, 25 or older                                               Historical cohort                                                            15-year survival
                                                              Ontario & California                                                            Random, registry-based                                                      50.2% vs 30.2%
                                                                      1988 to 2006                                                                                   36 & 41                                                                          RR = 1.66
                                                         Lowest income (%) tenth                                                       Age, stage & tumor size                                                    95% CI: 1.00, 2.76
Gorey et al. 2010a                         Lowest income (%) third                                                                    105 & 126                                                Received adjuvant radiation therapy
                                                                                                                                                                                                                                                                  42.7% vs 24.4%
                                                                                                                                                                                                                                                                       RR = 1.75
                                                                                                                                                                                                                                                                95% CI: 1.21, 2.53
Gorey et al. 2010b                        Breast cancer, 25 or older                                                             Historical cohort                                                             5-year survival
                                                              Ontario & California                                                            Random, registry-based                                                      80.3% vs 66.3%
                                                                      1998 to 2006                                                                                   50 & 50                                                                          RR = 1.21
                                                      High poverty neighborhoodsf                                                          Age, race & stage                                                         95% CI: 0.98, 1.50g
Gorey et al. 2010b                                               //                                                                                             49 & 49                                                          Received hormone therapy
                                                                                                                                                                                                                                                                  55.1% vs 31.2%
                                                                                                                                                                                                                                                                       RR = 1.77
                                                                                                                                                                                                                                                                95% CI: 1.12, 2.79
Gorey et al. 2009              Node positive breast cancer, 25 or older                                                Historical cohort                                         Received adjuvant radiation therapy
                                                              Ontario & California                                                            Random, registry-based                                                      60.3% vs 36.0%
                                                                      1998 to 2000                                                                                   95 & 94                                                                          RR = 1.68
                                                          Lowest income (%) third                                                                  Age & stage                                                               95% CI: 1.12, 2.54
Gorey et al. 2009                     Non-metastasized breast cancer                                                              110 & 163                                              Waited 60 days or more for treatment
                                                       Windsor, ON & Modesto, CA                                                                                                                                                         4.7% vs 9.7%
                                                                                                                                                                                                                                                                       RR = 2.08
                                                                                                                                                                                                                                                               95% CI: 0.87, 5.00g
                                                                                                                                                                                                                                              [RRpooled = 1.75, 95% CI: 1.49, 2.05]
Cystic Fibrosis
Stephenson et al. 2017                  Cystic fibrosis, all ages                                                                Historical cohort                                                                   Survival
                                                                    Canada & USA                                                               Population, registry-based                                                               nd
                                                                      2009 to 2013                                                                               4,662 & 205                                                                       HR = 4.35
                                                                 Uninsured in USA                                                               Age, gender, race, BMI                                                      95% CI: 2.70, 7.14
                                                                                                                                                        3 comorbidities & 5 biomarkers
BMI, body mass index; HR = hazard ratio; HR+, hormone receptor positive; Mdn, median; nd, no data; OR, odds ratio; RR, rate ratio; SEER, Surveillance, Epidemiology and End Results program; SES, socioeconomic
status. All income measures were ecological, census tract (CT)-based. All of the Ontario-California comparisons by Gorey et al. also accounted for place by sample stratification (large urban places, small urban places
or rural places) and for purchasing power differences (adjustments for Canadian-USA dollar and US Census Bureau poverty and Statistic Canada low-income definition differences). aPotential confounds that were
accounted for by sample restriction, matching or mathematical/regression modeling. bRisk ratios were adjusted in regressions or directly standardized. Risk ratios > 1.00 indicate a Canadian advantage while those <
1.00 indicate a USA advantage. c30% or more of the household were poor in the USA compared to similarly low-income neighborhoods in Canada. dDiagnosed early with node negative disease and received breast con-
serving surgery followed by radiation therapy. eReceived breast conserving surgery within two months of diagnosis and adjuvant radiation therapy with four months of surgery. f20% or more of the household were poor
in the USA compared to similarly low-income neighborhoods in Canada. g P<0.10.
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treatments and surviving were 36% greater than Americans. That
estimate was essentially unequivocal across all the reviewed stud-
ies and was larger than a previous meta-analytic estimate based on
less prevalently poor neighborhoods. Recalling that such a 36%
differential is implicated across most common health conditions
and diseases over the lives of millions of impoverished Canadians
and Americans, its population-level significance is clear. In addi-
tion to accounting for socioeconomic factors most of these primary
studies also accounted for key personal and contextual case-mix
differences between Canada and the USA, notably disease severity
and health care service endowments in diverse large to small urban
or rural places. We consider the robustness of the observed
Canadian advantage to be our review’s most provocative scholarly
and policy-significant finding. As with primary research, we think
that the interpretation of significant interaction effects or important
effect modifications ought to take precedence in synthetic
research. Therefore, we think four more interpretive adjuncts are in
order. First, larger Canadian advantages were replicated among
socioeconomically vulnerable patients with acute conditions and
chronic diseases, representing a multiplicative Canadian advantage
among those living in poverty with chronic diseases. Such patients
probably had multiple experiences with their respective health care
system over several years. In other words, it seems that the longer
patients were in contact with their respective Canadian or
American health care systems, the larger were their respective
advantages or disadvantages. Second, three studies included four
assessments of wait-lists, estimating that the exemplary risks of
experiencing relatively long waits for adjuvant cancer care or of
dying while waiting for a liver transplant were much greater in the
USA (RRs ranged from 1.89 to 2.99, precision-weighted RR=2.36,
95% CI 2.09-2.66) than in Canada.40,44,47 This evidence stands in
stark contrast to prevalent contemporary political rhetoric. Third,
all this field’s synthetic evidence strongly suggests a dose-response
relationship between socioeconomic vulnerability and Canadian
advantages. It seems, therefore, that Canada’s single payer health
care system causally provides much better health care than does
the USA’s multiple payer system that still leaves millions unin-
sured or inadequately insured. The Canadian health care system’s
most pronounced evidence-based advantages are clearly among
those who live in poverty who consistently experience much better
health care compared to impoverished Americans. In short, the
more socioeconomically vulnerable a person is the more protective
a single payer health care system is likely to be.
The fourth interpretive adjunct arose serendipitously in our
systematic search for eligible studies. We retrieved 8 within-
Canada studies of socioeconomic factors and cancer care.48-55
Though ineligible for this review, these studies were very interest-
ing. One observed a modest indirect low-income-care association.
Five others observed similar trends, but were not statistically sig-
nificant and two others were null. The pooled precision-weighted
estimate was minuscule (RR=0.97, 95% CI 0.95-0.99). We identi-
fied more than 100 such within-USA studies nearly all of which
observed the well-known, large American socioeconomic-care gra-
dient. Six studies that were included in this review, but that also
observed typically very low-income or poverty associations with
cancer care in both Canada and the USA allowed for a controlled,
precision-weighted synthetic comparison.31,41,43,45-47 A large disad-
vantage of being poor was observed in the USA (RR=0.73, 95% CI
0.71-0.75) while no such association was observed in Canada
(RR=0.99, 95% CI 0.96-1.02), z=14.44, P<0.05. Such within-
country observations clarify the between-country comparisons.
Given the intimate relationship between low socioeconomic status
and health insurance inadequacy in the USA,56-58 but not in
Canada, the pattern resolutely identifies inadequate health insur-
ance coverage in the USA as the primary explanation for this
study’s findings. It clearly indicts the USA for the largely inade-
quate health insurance coverage it provides its underclass,11
including those who live in poverty or near poverty as well as the
                                Reviews and Meta-Analysis
Table 4. Participant and study characteristics: 34 study outcomes
included in the meta-analysis.
                                                                               N.                %
Acute conditions or chronic diseases studied                                              
       Acute heart failure/myocardial infarction                       2                     5.9
       Appendicitis                                                                           2                     5.9
       Asthma                                                                                    1                     2.9
       COPD (urgent care)                                                            1                     2.9
       Cataract surgery                                                                   1                     2.9
       Gastroschisis (NICU care)                                                1                     2.9
       Cancera                                                                                  17                   50.0
       Kidney failure/ESRD                                                            3                     8.8
       Cystic fibrosis                                                                        3                     8.8
       Heart failure/heart disease                                                2                     5.9
       Liver disease                                                                         1                     2.9
Participant ages                                                                                                     
       Adults 18 to 25 or older                                                      21                   61.8
       Older adults 50 to 65 or older                                           6                    17.6
       All people (children and adults)                                      4                    11.8
       Children less than 18 years of age                                   2                     5.9
       Infants                                                                                     1                     2.9
Sampling frame: Canada vs USA                                                                        
       Single province vs single stateb                                       10                   29.4
       Nation vs nationc                                                                   9                    26.5
       Single provinced vs nationc                                                 6                    17.6
       Three or more provinces and states                               4                    11.8
       Single metropolitan arease                                                4                    11.8
       Single metropolitan areae vs nation                                 1                     2.9
Cohort initiation                                                                                                    
       1980s                                                                                        2                     5.9
       1990s                                                                                       22                   64.7
       2000s                                                                                        6                    17.6
       2010s                                                                                        4                    11.8
Research design                                                                                                    
       Retrospective cohortf                                                         28                   82.4
       Prospective cohortg                                                             6                    17.6
Aggregate analytic sampleh                                                                                 
       < 100                                                                                        3                     8.8
       00 to 999                                                                                 10                   29.4
       1,000 to 24,999                                                                       13                   38.2
       ≥ 25,000                                                                                   8                    23.5
Number of covariatesi                                                                                          
       2 or 3                                                                                       12                   35.3
       4 to 9                                                                                       13                   38.2
       10 to 15                                                                                    9                    26.5
Study outcome                                                                                                       
       Treatment accessj                                                               10                   29.4
       Survival/mortality/failure, < 1 year                                   9                    26.5
       Survival/mortality/failure, 1 to 5 years                             8                    23.5
       Survival/mortality/failure, > 5 to 15 years                       7                    20.6
COPD, congestive obstructive pulmonary disease; ESRD, end-stage renal disease; NICU, neonatal inten-
sive care unit. aCancer of the breast (7), colon (6), lung (3) and upper aerodigestive tract (1).  bAll were
Ontario and California; Windsor, ON vs Modesto, CA was embedded within one. cFour were based on the
Surveillance, Epidemiology and End Results (SEER) program. dFive were Ontario and one was Manitoba. 
eOttawa, ON vs Rochester, MN; four were Toronto, ON vs San Francisco, CA. fUsed secondary/adminis-
trative/registry data and all but one were population-based. gMore commonly used primary data and were
either clinic- or population-based.h27 of 34 (79.4%) lost < 1% to follow-up, 5 (14.7%) ≤10%, and 2 did not
report. iPotential confounds accounted for by sample restriction, matching or regression modeling. 
j 3 of the 10 treatment measures included some assessment of wait times.
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periodically unemployed or underemployed middle-class. Most
regrettably, this indictment holds true in post-Affordable Care Act
America. For example, at the time of this writing, 14 states still had
not fulfilled the Act’s legislative intent to expand Medicaid. 
Potential limitations and future research needs
Primary research
Although primary studies in this field were generally not able
to directly account for race/ethnicity, mainly due to the lack of
such data in Canada, some of them replicated their findings by
comparing subsamples of non-Hispanic white patients in the USA
with racially and ethnically diverse Canadian samples.31,41,42,44-46
Large Canadian advantages were still observed in these samples,
thereby validating the socioeconomic and health insurance expla-
nations found in this study. But this does not mean that race does
not matter for the following reasons. Each nation has had unique
histories of oppression leaving certain racialized minority groups
relatively more socioeconomically vulnerable: Indigenous First
Nations, Inuit and Métis people in Canada and African Americans
in the USA. Racialized disparities in health and health care clearly
persist in both countries, but they seem relatively muted in
Canada.59-61 In fact, the phenomenon known as the Hispanic para-
dox, that is − the health protective effects of being Hispanic despite
living in poverty − may be stronger in Canada.62 The Indigenous-
non-Hispanic white divide, however, seems significantly wider in
Canada. Precisely how specific racialized group statuses matter in
Canada-USA comparative heath care is not yet known because
research questions about the unique experiences of racialized sub-
populations have not yet been posed. Their future incorporation
would further magnify this field’s human and policy significance.
Notwithstanding the noted incremental strengths of this field’s
research over the past 15 years, it provided predominantly histori-
cal cohort-based knowledge about the experiences of Canadian
and American patients in the 1990s to 2000s. Prospective cohorts
were represented more prevalently than in previous reviews, but
remained uncommon. Retrospective studies can be methodologi-
cally limited, but we believe that the advancement of confirmed
historical insights is critical in planning future research and poli-
cies. Also, we were comforted by the fact that the findings of the
reviewed retrospective and prospective cohorts did not differ sig-
nificantly. Still, well-controlled prospective cohorts are clearly
needed. A prospective cohort-based research agenda representative
of Canada and the USA emphasizing both internal and external
validity would undoubtedly be quite expensive. However, such an
investment holds the promise of huge knowledge dividends. It
could, for example, provide valuable evidence about the relative
effects of expanding Medicaid (or not) in the USA and the effects
of increasing private options (or not) in Canada. Given the long-
standing and often contentious policy debates on health care across
North America, such a well-funded research agenda seems long
overdue. 
Synthetic research
Though its sampling frame included unpublished sources, this
meta-analytic sample ultimately included only published studies.
One may legitimately wonder if publication bias could be a potent
alternative explanation for its findings. However, this seems
improbable for the following reasons. First, this review’s hypothe-
sis of advantaged Canadian health care specific to socioeconomi-
cally vulnerable patients was not the primary hypothetical concern
of the majority of its included studies. In addition, the review
hypothesis of greater Canadian advantages among those with
chronic diseases was not advanced by any of the primary studies.
Secondly, 6 of the 34 study outcomes reviewed were null and one
of the review’s synthetic findings (i.e., 7-study pooled estimate of
acute care of all patients, impoverished to affluent) was nearly null.
Those are precisely the sort of findings one would not readily
expect to retrieve from published studies if publication bias, that is,
a preference to publish significant findings, was potent. This field’s
editorial review boards seem to have been open to publishing null
findings. Third, it seems improbable that publication bias could
account for such a complex pattern of pooled effects moderated by
disease chronicity within patient socioeconomic statuses as is dis-
played in Table 5. Building upon this modestly funded rapid
review, a well-endowed full systematic review might consider
expanding its gray literature/unpublished research sampling frame.
Future synthetic analysts might start by searching relevant annual
meetings or conferences as well as diverse organizations; grass-
roots, non-profit or governmental, for the findings of researchers
and/or knowledge users. A snowball survey of such key informants
could bolster the internal and external validity of such a review. In
                             [Journal of Public Health Research 2019; 8:1479]                                                 [page 9]
                                                                                               Reviews and Meta-Analysis
Table 5. Summary of Canada-USA comparative study outcomes.
                                                                                                                                           Study risk ratios            Pooled
No. of study outcomes                                                    Tot. participants            Min.            Max.        Median          Risk ratio      95% CI
Overall population comparisons, tot                                                             438,482                            0.30                  2.86                1.08                        1.09a              1.08-1.10
19                     
Acute conditions                                                                                                 173,408                            0.30                  1.99                1.00                       1.03bd             1.02-1.04
7                       
Chronic diseases                                                                                                265,074                            0.53                  2.86                1.14                       1.12cd             1.11-1.13
12                     
Socioeconomically vulnerable population comparisons, tot                     78,589                             1.07                  4.35                1.66                        1.36a              1.35-1.37
15                     
Acute conditions                                                                                                  53,836                             1.14                  1.14                1.14                       1.14be             1.05-1.23
1                       
Chronic diseases                                                                                                 24,753                             1.07                  4.35                1.67                       1.37ce             1.36-1.38
14                     
Pooled risk ratios with the same superscripts were compared: az = 48.47, bz = 4.79, cz = 41.48, dz = 22.50 and ez = 8.94, all P<0.05. 
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addition to collecting data missing from primary study reports it
could facilitate the retrieval of knowledge from unpublished stud-
ies that may presently sit in respondent’s file drawers or those of
their colleagues or professional acquaintances. For its admitted
rapidity, this systematic review may be limited in other ways. A bit
more of its practical context may illuminate them. First, this syn-
thesis was essentially unfunded. Second, we began by scoping all
the research on any health status or health care difference between
any two high-income countries. The voluminous results of those
preliminary searches in addition to funding constraints caused us
to focus on a rapid review of the most scholastically interesting,
politically important and feasible research: Health care in Canada
and the USA. We planned exhaustive searches, but of focused
questions within rigorous methodological constraints and a stream-
lined meta-analysis. We think that these are strengths of this rapid
review. However, in doing so we did not adhere to at least two pre-
ferred systematic review and meta-analytic methods. As three
reviewers independently searched for eligible studies, informally
sharing their developing methods throughout the process, we did
not produce a unified flow chart, detailing each step of the infor-
mation gathering process. Also, reviewers were not blinded to pri-
mary study findings. Recall though that each step of the review
process − study selection, data abstraction and meta-analysis − was
initially cross-validated by at least two reviewers. Consensus was
ultimately reached on all selected studies. And 9 of 34 of the pri-
mary study outcomes we ultimately included were counter hypo-
thetical, that is, they did not support our review’s central hypothe-
sis of Canadian advantage. For these reasons we believe that our
rapid systematic review approximates the validity of a full system-
atic review. A better-endowed full systematic review, accom-
plished by independent reviewers, would be most welcome. Such
systematic replications are the hallmark of sound scientific inquiry,
primary and synthetic. 
Conclusions
This field’s research now seems rigorous enough to support
confident judgements about the relative effectiveness of Canadian
versus American health care, especially among the most socioeco-
nomically vulnerable. Socioeconomically vulnerable Canadians
are consistently and highly advantaged on health care access and
outcomes compared to their American counterparts. Less vulnera-
ble comparisons found more equivocal and more modest Canadian
advantages. The Affordable Care Act ought to be retained, indeed
fully supported, including the envisioned expansion of Medicaid
across all states. When politically achievable, however, single
payer health care would better ensure truly equitable access and
outcomes among America’s diverse population. Canada’s single
payer system ought to be maintained and strengthened where need-
ed, but not through the addition of private tiers.
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